BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Sarcomas AND TOP2A, TOP2, TP2A AND Treatment
11 results:

  • 1. Pharmacogenetics of the Primary and Metastatic Osteosarcoma: Gene Expression Profile Associated with Outcome.
    Trujillo-Paolillo A; Tesser-Gamba F; Seixas Alves MT; Filho RJG; Oliveira R; Petrilli AS; Toledo SRC
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982681
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. In vitro anti-synovial sarcoma effect of diallyl trisulfide and mRNA profiling.
    Xia SL; Ma ZY; Wang B; Gao F; Yi CG; Zhou XX; Guo SY; Zhou L
    Gene; 2022 Mar; 816():146172. PubMed ID: 34995734
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.
    Godel M; Morena D; Ananthanarayanan P; Buondonno I; Ferrero G; Hattinger CM; Di Nicolantonio F; Serra M; Taulli R; Cordero F; Riganti C; Kopecka J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599901
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities.
    Crane E; Naumann W; Tait D; Higgins R; Herzog T; Brown J
    Int J Gynecol Cancer; 2020 Apr; 30(4):480-484. PubMed ID: 32114514
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
    Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
    Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Expression and inhibition of BRD4, EZH2 and top2a in neurofibromas and malignant peripheral nerve sheath tumors.
    Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
    PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
    Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
    Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
    Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
    Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
    Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
    J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Sensitivity to top2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.
    Lu H; Hallstrom TC
    PLoS One; 2012; 7(8):e42921. PubMed ID: 22900064
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.
    Crago AM; Singer S
    Curr Opin Oncol; 2011 Jul; 23(4):373-8. PubMed ID: 21552124
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.